These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 10645473)

  • 21. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease.
    Leone P; Janson CG; McPhee SJ; During MJ
    Curr Opin Mol Ther; 1999 Aug; 1(4):487-92. PubMed ID: 11713764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Canavan disease (aspartoacylase deficiency)].
    Kobayashi K; Tsujino S
    Ryoikibetsu Shokogun Shirizu; 2001; (36):118-21. PubMed ID: 11596340
    [No Abstract]   [Full Text] [Related]  

  • 23. Reliable prenatal diagnosis of Canavan disease by measuring N-acetylaspartate in amniotic fluid using liquid chromatography tandem mass spectrometry.
    Al-Dirbashi OY; Kurdi W; Imtiaz F; Ahmad AM; Al-Sayed M; Tulbah M; Al-Nemer M; Rashed MS
    Prenat Diagn; 2009 May; 29(5):477-80. PubMed ID: 19235826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canavan disease: a monogenic trait with complex genomic interaction.
    Surendran S; Michals-Matalon K; Quast MJ; Tyring SK; Wei J; Ezell EL; Matalon R
    Mol Genet Metab; 2003; 80(1-2):74-80. PubMed ID: 14567959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings.
    Matalon RM; Michals-Matalon K
    Front Biosci; 2000 Mar; 5():D307-11. PubMed ID: 10704428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of Canavan disease with microcephaly.
    Gowda VK; Bhat MD; Srinivasan VM; Prasad C; Benakappa A; Faruq M
    Brain Dev; 2016 Sep; 38(8):759-62. PubMed ID: 26992473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of Canavan-Van Bogaert-Bertrand leukodystrophy].
    Mikhaĭlova SV; Zakharova EIu; Bukina AM; Il'ina ES; Pokrovskaia AIa; Fedoniuk ID; Bembeeva RTs; Petrukhin AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(4):50-4. PubMed ID: 15270300
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
    McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canavan disease: studies on the knockout mouse.
    Matalon R; Michals-Matalon K; Surendran S; Tyring SK
    Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protracted course of N-acetylaspartic aciduria in two non-Jewish siblings: identical clinical and magnetic resonance imaging findings.
    Zafeiriou DI; Kleijer WJ; Maroupoulos G; Anastasiou AL; Augoustidou-Savvopoulou P; Papadopoulou F; Kontopoulos EE; Fagan E; Payne S
    Brain Dev; 1999 Apr; 21(3):205-8. PubMed ID: 10372908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of structural biology on neurobiology.
    Viola RE
    Proc Natl Acad Sci U S A; 2007 Jan; 104(2):399-400. PubMed ID: 17213329
    [No Abstract]   [Full Text] [Related]  

  • 32. The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients.
    Elpeleg ON; Shaag A
    J Inherit Metab Dis; 1999 Jun; 22(4):531-4. PubMed ID: 10407784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Canavan disease (aspartoacylase deficiency)].
    Kobayashi K; Sakuragawa N
    Ryoikibetsu Shokogun Shirizu; 1998; (18 Pt 1):385-8. PubMed ID: 9590077
    [No Abstract]   [Full Text] [Related]  

  • 34. Canavan disease: a white matter disorder.
    Kumar S; Mattan NS; de Vellis J
    Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms.
    Baslow MH; Resnik TR
    J Mol Neurosci; 1997 Oct; 9(2):109-25. PubMed ID: 9407392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular basis of Canavan's disease: from human to mouse.
    Surendran S; Matalon KM; Tyring SK; Matalon R
    J Child Neurol; 2003 Sep; 18(9):604-10. PubMed ID: 14572138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.
    Kaul R; Gao GP; Balamurugan K; Matalon R
    Nat Genet; 1993 Oct; 5(2):118-23. PubMed ID: 8252036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
    Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
    J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A benign polymorphism in the aspartoacylase gene may cause misinterpretation of Canavan gene testing.
    Propheta O; Magal N; Shohat M; Eyal N; Navot N; Horowitz M
    Eur J Hum Genet; 1998; 6(6):635-7. PubMed ID: 9887384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic resonance imaging in juvenile Canavan disease.
    Toft PB; Geiss-Holtorff R; Rolland MO; Pryds O; Müller-Forell W; Christensen E; Lehnert W; Lou HC; Ott D; Hennig J
    Eur J Pediatr; 1993 Sep; 152(9):750-3. PubMed ID: 8223809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.